LAUNCH EXCELLENCE
From early planning to post-launch performance.
Most launches have one window to get the trajectory right. phamax helps you see every dimension, surface missed potential, and act with confidence before the window closes.
100+ Rare disease projects in EU since 2014     |      10+ European markets covered     |      Powered by AI.     Grounded in pharma expertise.
phamax brings together pharma-structured data, a decade of launch strategy experience, and AI. See every dimension of your launch. Detect what is going wrong earlier. Decide with confidence.
OUR PRACTICE
In EU rare disease and specialty care, launch performance depends on connecting market intelligence, access signals, competitive dynamics, and KOL activity into one picture before the planning window closes. phamax uses AI-enabled automation to do that faster, and a decade of EU launch experience to interpret what the signals mean. The output is a prioritised action plan, not a report.
AI-enabled automation connects market intelligence, access signals, patient pathway data, and competitive dynamics in days, not weeks. A decade of EU rare disease and specialty care experience interprets what the signals mean. The output is a prioritised action plan with a clear view of where the launch stands and what to do next.
AI holds all dimensions simultaneously. Your decisions are faster and better informed.
How phamax works
03
Market access, patient pathways, competitive dynamics, KOL engagement, reimbursement timelines, field deployment. A product launch runs across all of them simultaneously. Collecting, correlating and standardising data across every dimension takes time that most launch cycles cannot afford. 80% of launches continue as they start in the first six months. There is rarely a second chance to reset the trajectory.
01
The landscape
Every launch dimension matters. Most processes can only track a few at once.
Hospitals, channel partners, licensed partners, payers and reimbursement bodies each hold a different piece of the launch picture. Each operates on different data structures, different reporting cadences, and different definitions of the same metric. By the time that data is consolidated into something a commercial team can read, the signal has aged. The root cause of a performance gap is identified in the quarterly review, not before it.
Different systems. Different partners. Different definitions. One incomplete picture.
How most teams work
02
The launch landscape has moved with AI. Have you evolved?
The case for a different approach
EU pharma launches are harder, faster, and more fragile than they were a decade ago. Most commercial models have not kept pace. phamax has.
The phamax launch system
Three moments where launch teams need sharper decisions.
Pre-Launch
3-4 years to launch
Prepare: define where to play before investment decisions harden.
Build the evidence base, patient opportunity view, and access strategy early enough to shape launch sequencing and commercial resource choices.
-
Opportunity sizing, patient segmentation and pathway mapping.
-
Payer value assessment, analog benchmarking and launch sequencing.
-
GTM design, customer segmentation and cross-functional alignment.
Launch Monitoring
Go-live to month 6
Monitor: read early signals before they become launch patterns.
Create a measurement rhythm that shows whether uptake, access, account activation, and field activity are moving in the right direction.
-
KPI framework, reporting cadence and escalation thresholds.
-
Account activation, access milestone and field activity tracking.
-
Course-correction recommendations inside the planning cycle.
phamax supports the three points where launch decisions carry the highest commercial consequence: how to prepare, how to monitor, and where to act next.
Post-Launch Diagnostic
0-12 months post-launch
Act: explain performance variance and prioritise what to do next.
Connect sales, patient opportunity, access, pathway, account, and field inputs to show why performance varies and where commercial focus should move.
-
Performance vs. opportunity analysis at regional and account level.
-
Patient pathway, diagnostic and institutional bottleneck identification.
-
Priority region, institution and account list with leadership recommendations.
From fragmented evidence to decision-ready action.
Powered by AI. Grounded in pharma.
AI accelerates evidence assembly and synthesis. phamax experts own the interpretation, commercial judgement and final recommendation.
​Client decision question
Start with the right commercial question: where to play, who to prioritise and how to act.
​Evidence + data inputs
​Assemble market research, epidemiology, access, sales, account, CRM and competitive evidence.
AI-supported synthesis
Accelerate pattern detection, signal finding, evidence structuring and cross-workstream synthesis.
Consultant challenge
Senior consultants challenge assumptions, add pharma context and pressure-test the findings.
Decision-ready recommendation
Convert the diagnosis into clear recommendations, next steps and a leadership presentation.
From fragmented launch inputs to decision-ready action.
Client challenges
Rare Disease
100+
projects across European markets since 2014
Haemophilia, lysosomal storage disorders, muscular dystrophy, hereditary angioedema, primary sclerosing cholangitis
Oncology
Deep oncology
experience
across six
indications
Breast, gastric, renal cell, hepatocellular, lung and pancreatic cancer
EU Market Depth
10+
European markets
covered
Germany, France, UK, Netherlands, Switzerland, Nordics and additional EU markets
phamax works with emerging pharma and launch-stage biotechs building their first commercial infrastructure, as well as Top-20 affiliate teams managing multi-market EU launches.
Post-launch diagnostic case study
Rare-disease oncology. Germany. 200+ brick-level regions.
200+
regions analysed
4
diagnostic lenses
6 wks
to recommendation
A rare-disease oncology product launched across Germany. National reporting showed early traction but could not explain regional post-launch variance in uptake.
​
phamax connected sales, patient pathway data, access status and field activity across 200+ brick-level territories.
Output:Â A prioritised territory action plan that redirected commercial investment to the highest-potential areas within six weeks.
Launch Excellence Assessment
Know where your launch readiness is strongest. And where it is exposed.
60 – 80 pts
Launch Ready
Full diagnostic scope. Discuss next steps with a launch expert.
35 – 59 pts
Launch Developing
Focused diagnostic possible. Some data assembly may be needed.
10 questions. Five minutes. Receive a Launch Excellence score and a recommendation on whether your team is ready for a full diagnostic, a focused review, or a measurement foundation sprint.
0 – 34 pts
Launch Foundation
Measurement foundation sprint
recommended first.
Insights & latest